What the Latest Clinical Trial Results Show According to publicly reported late-stage trial data: Participants receiving higher doses achieved average weight loss approaching 2530% over approximately 68 weeks Some individuals lost more than 70 pounds during the study period Participants with obesity and knee osteoarthritis also reported significant reductions in joint pain These outcomes exceeded the average weight loss typically reported in clinical trials of currently approved GLP-1 medications
6 The coexistence of underlying predisposing genes, such as PNPLA3, TM6SF2 and others, seems to increase the risk for development of DM2 as well as of NAFLD
Rights and permissions About this article Cite this article Askarpour, M., Hadi, A., Dehghani Kari Bozorg, A
Rybelsus and pregnancy & breastfeeding If you are pregnant or trying to be, do not take Rybelsus
Adding a second glucose-lowering compound to a person already struggling with hypoglycemia is not a sensible approach
Avoid the inner thigh, where skin is thinner